Form 4: Neuronetics EVP Granted 210,000 Restricted Stock Units

Neuronetics, Inc. Executive Vice President, Chief Legal Officer, and Corporate Secretary William Andrew Macan received a grant of 210,000 restricted stock units.

Summary

• William Andrew Macan, EVP, CLO, and CS of Neuronetics, Inc. (STIM), was granted 210,000 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this grant is February 23, 2026.
• The RSUs will vest in three equal annual installments, commencing on February 23, 2027.
• Vesting is contingent upon the Reporting Person's continuous service to the company through each vesting date.
• Each RSU represents a contingent right to receive one share of Neuronetics' common stock.
• Following this reported transaction, William Andrew Macan beneficially owns 883,561 shares of Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the strong alignment of executive incentives with long-term shareholder value and executive retention, which are generally favorable for corporate stability and growth.

Positives

• The grant of Restricted Stock Units (RSUs) aligns the executive's long-term interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• The multi-year vesting schedule (three equal annual installments) serves as a retention mechanism, incentivizing the executive to remain with the company and contribute to its sustained success.

Negatives

• The RSU grant represents potential future dilution for existing shareholders when the units vest and convert into common stock.
• The executive does not receive immediate cash value from this grant, as it is equity-based and vests over time.

Risks

• The RSUs are subject to forfeiture if the Reporting Person's continuous service to the company terminates before the vesting dates.

Future Outlook

The RSU grant, with its multi-year vesting schedule, indicates a long-term commitment from the executive to Neuronetics and aligns their future financial incentives with the company's performance and shareholder value creation.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) is a standard practice in executive compensation across various industries, particularly in technology and medical device sectors like Neuronetics. This method is widely used to attract, retain, and incentivize key executives by linking their compensation directly to the company's long-term stock performance and ensuring continued service.

Comparison to Industry Standards

• N/A for this specific filing as it details a single executive compensation grant without broader context for industry comparison of overall compensation packages or specific performance metrics.

Stakeholder Impact

• Shareholders: Potential future dilution upon the vesting and conversion of RSUs into common stock.
• Employees (Executive): Provides a significant long-term incentive and retention mechanism, aligning their financial interests with the company's success.

Next Steps

• The RSUs will begin to vest in three equal annual installments starting on February 23, 2027, subject to continuous service.

Key Dates

Keywords

Neuronetics, STIM, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Corporate Governance